secwatch.observer — SEC 8-K summary
======================================

Issuer:     Vir Biotechnology, Inc. (VIR)
CIK:        0001706431
Form:       8-K
Filed at:   2025-12-16T23:59:59+00:00
Accession:  0001628280-25-057394
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vir Bio licenses CHD combo to Norgine for EUR 55M upfront, up to EUR 495M milestones; cash runway extended to Q4 2027
--------------------------------------------------------------------------------

- Exclusive commercial license for tobevibart+elebsiran in Europe, Australia, New Zealand for chronic hepatitis delta.
- Vir receives EUR 55M upfront, up to EUR 495M in milestones, plus tiered mid-teen to high-twenties % royalties.
- Norgine to cover ~25% of go-forward external costs for ECLIPSE registrational program.
- SOLSTICE Phase 2 data: 66% of CHD patients achieved HDV RNA target not detected at 48 weeks; well-tolerated.
- Vir expects current cash, equivalents, and investments to extend into Q4 2027 under current operating plan.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1706431/000162828025057394/0001628280-25-057394-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1706431/000162828025057394/vir-20251216.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-057394

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer